Cedo Reveals Roadmap for Sustainable Business Growth
20.9.2021 10:00:00 EEST | Business Wire | Press release
Cedo, one of Europe’s largest manufacturers of recycled plastic waste bags has today revealed its Roadmap for Sustainable Business Growth. The plan is built on three pillars: People, Planet and Products and comes with targets designed to protect the earth’s resources while attracting and nurturing talent within the business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005048/en/
Cedo CEO, Rik De Vos, says “Cedo is proud of our contribution to achieving the goals of sustainable business development outlined by the UN” (Photo: Business Wire)
“Our plan has been built with deep engagement from all the employees within our company,” says Rik De Vos, CEO of Cedo. “The journey to circularity will not be easy, but I have seen an immediate shift in decision making, and prioritisation of actions now that we are a purpose-led business. We are actively contributing to European and UK legislative debate to accelerate this transformation, while articulating and communicating proactively and transparently. A dream has been turned into a great journey and it pleases me enormously to see the response from everybody on our ambition.”
People
To better serve customers and employees, Cedo is committing to become positively involved in its communities in the seven countries in which it operates, investing in them both as an employer and community member while actively supporting local environmental, health and wellness projects.
With its industry-leading focus on sustainability and rewarding career and development opportunities, Cedo hopes to attract fresh and diverse talent to join its two thousand-strong workforce who are as committed to environmental sustainability as they are to innovation. “We recognise that our economic growth as a business can only be delivered by valued colleagues and communities, high quality products and a healthy planet. Our pillars are aligned to these beliefs. Real success can only come from delivering progress in all three areas,” De Vos said.
Planet
For planet, the business has committed to achieving climate neutrality across its global operations by 2030, increasing its use of renewable energy and improving energy efficiency usage.
Cedo will also improve its stewardship of water, with clear monitoring and improvement plans while reducing the overall water consumption in its operations. The business aims to send zero waste to landfill and has already achieved this target this year in the UK.
Product
To achieve circularity, Cedo has pledged to use only recycled, recyclable or sustainable materials for both packaging and product design. “We will use the Ellen MacArthur Foundation’s Circulytics measurement tool, transparently tracking its progress to become a circular business,” says Ton Emans, Director of Recycling at Cedo and President of Plastics Recyclers Europe. “We’ve been members of the Ellen MacArthur Foundation and participants of the New Plastics Economy initiative since its inception in 2016 and by working together we are confident that we can transition from a linear to a circular business model over the next few years.”
Working with customers in 34 countries and listening to their needs, Cedo is aiming to dramatically reduce plastics in its products and focus better on the use of raw materials through its eco-design process, selecting the appropriate raw material for each product and its intended life cycle. Going forward, the business will only purchase from suppliers which meet its ethical, environmental and social standards.
All of these steps that Cedo is taking towards sustainable business growth will be measured and shared in a new, fully transparent Grow With Purpose report, released every year.
Supporting nine of the United Nations Sustainable Development Goals
As well as outlining its approach to doing business, Cedo’s Roadmap for Sustainable Business Growth explains how it will work towards nine of the United Nations Sustainable Development Goals. These are Goal 3, Good Health and Well-Being; Goal 5, Gender Equality; Goal 8, Decent Work and Economic Growth; Goal 9, Industry, Innovation and Infrastructure; Goal 12, Responsible Consumption and Production; Goal 13, Climate Action; Goal 14, Life Below Water; Goal 15, Life On Land and Goal 16, Peace, Justice and Strong Institutions.
In July 2021, Cedo announced that it is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005048/en/
Contact information
For further information please contact Miki Haines-Sanger on +44 7900 690 574 / miki@goldengoosepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
